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signiﬁcantly more likely to experience an ER visit or an inpatient stay compared to 
patients in capitated plans (odds ratio for ER visit: 1.64, p < 0.05; odds ratio for an 
inpatient stay: 1.11, p < 0.05). CONCLUSIONS: The results of this study conﬁrm 
that utilization rates are higher in FFS plans; however, the strength of the association 
was not as robust when the regression models were adjusted for propensity score. 
Capitated plans seek to reduce resource utilization.
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OBJECTIVES: This paper compares physician’s cost awareness of types of payments 
and insurance status at the point of visit, using two analytical datasets extracted from 
the National Ambulatory Medical Care survey (NAMCS) on patients diagnosed with 
Type II diabetes without complications. It analyzes the effects of various changes in 
the physician survey. METHODS: Two analytical datasets are constructed for diabetic 
patients Type II with no complication identiﬁed with code 25.00, one of 694 individu-
als in 1996 and one of 620 for 2005. Pharmacological treatment has been deﬁned by 
building two drug lists for 1995/1996/1997 and 2004–2005–2006 from Facts and 
Comparisons books (one year before - one year after the year of reference) and the 
Brixner et als study (2008). Drug codes used for the two periods are generic codes. 
The coding has been revised in order to integrate the withdrawal of FDA codes and 
the transition to new Multum drug classiﬁcation system. A disease economic model 
is used. Dependent variables represent access and use of drug therapy. RESULTS: 
Drug codes for the two references periods substantially differ. New development of 
the disease model are described between 1996 and 2005 to integrate these drug codes 
changes,the introduction of electronic records, new types of ﬁnancial information, new 
beneﬁt designs and changes of clinical guidelines. It transforms the previous series of 
cross sectional modeling tested on 3 chronic conditions into a time series and dynamic 
framework. The model describes prescribing patterns of new versus old classes (espe-
cially TZD and new insulin analogs), evolution of modes of administration and impact 
of electronic records. CONCLUSIONS: The paper contributes to show the interest of 
disease modeling not only by medical schools but also with an economic perspective. 
Even after triages from health care administrators for categorization of patients into 
various health plans, physicians are cost aware at the time of visit and this inﬂuences 
their prescribing decisions.
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OBJECTIVES: Prevention or mediation of adverse events can signiﬁcantly impact a 
patient’s quality of life and their employer’s health care costs. Decision modeling can 
be utilized to map pharmacists interventions provided through an employee-sponsored 
medication therapy management (MTM) program and calculate consequent cost 
savings associated with improved clinical outcomes. METHODS: A total of 700 
employees from 2 employer groups participate in a pharmacist provided MTM 
program. A team of clinicians and researchers classiﬁed and created codes for speciﬁc 
pharmacist interventions, resultant physician and/or patient responses, and consequent 
outcomes. Data was extracted from patient charts and entered into Microsoft Excel. 
Costs associated with each decision outcome were calculated from claims data. A 
one-year decision-analytic model was constructed using TreeAge Pro Suite 2008 to 
identify the cost savings per intervention. RESULTS: A total of 218 interventions were 
made by the pharmacists. The most frequently used interventions were “explained and 
advised the use of pattern management” (N = 95, 43.4%) and “alerted the physician 
of an abnormal A1c level” (N = 64, 29.2%). Cost savings resulting from diabetic 
interventions for ER visits ($71.00 – $337 PPPY), inpatient hospitalization ($460.00 
– $2360.00 PPPY), and total costs ($26.00 – $274.00 PPPY). All but one intervention 
resulted in a loss of cost savings for ofﬁce visits, indicating that patients visited spe-
cialty physicians more often after beginning the program. The total cost savings for 
these interventions were $165.00 PPPY and $145.00 PPPY, respectively. CONCLU-
SIONS: This decision-analytic model can be used as a rubric for providers seeking the 
most effective interventions to utilize for MTM programs, thereby reducing trial-and-
error and diminishing health care costs. The model illustrates the potential return on 
investment the employer realized as a result of sponsoring employee participation in 
this program.
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OBJECTIVES: Literature suggests that while pharmacists may be viewed as the most 
trusted health care professionals by patients, other health care professionals may 
often fail to trust them with making decisions regarding drug therapy regimens. 
Limited information is available regarding physicians’ therapy decisions based on 
pharmacist’s recommendations and the resulting patient clinical outcomes. This study 
aimed at ﬁnding if physicians’ therapy decisions based on pharmacist’s recommenda-
tions lead to optimal patient outcomes. METHODS: Approximately 700 employees 
from 2 employer groups have participated in an employer-supported pharmacist 
provided disease state management program. The program is provided at seven 
independent pharmacies across Northwest Ohio. A team of clinical pharmacists and 
researchers classiﬁed and created codes for speciﬁc pharmacist-provided interventions, 
resultant physician and/or patient responses, and consequent outcomes. Data was 
extracted from patient charts and entered into Microsoft Excel. Frequencies and 
percentages of pharmacists’ interventions, physicians’ responses and outcomes were 
calculated using SPSS ver. 17.0. A decision tree was created using TreeAge Pro Suite 
2008 to map interventions to responses to improved/unimproved outcomes. 
RESULTS: A total of 446 pharmacist interventions with corresponding physician 
responses and patient outcomes were made. The most frequent interventions involved 
drug therapy (N = 138, 31%) and formulary management (N = 105, 23.5%). The 
most frequent responses by physicians were “physician acknowledged recommenda-
tion, monitoring added” (N = 58, 13%) and “physician added a medication” (N = 
51, 11.4%). Physicians responded favorably to the pharmacists’ interventions 54.1% 
of the time. When physicians responded favorably, an improvement was seen in 
91.2% of patient outcomes compared to only 64% when physicians declined or did 
not respond to pharmacists’ interventions. CONCLUSIONS: Positive health out-
comes result from therapy decisions made by physicians following pharmacists’ 
recommendations. In an effort to save costs and improve care, pharmacist-physician 
collaboration is essential.
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OBJECTIVES: To evaluate selected Healthcare Effectiveness Data and Information 
Set (HEDIS) comprehensive diabetes care measures in the i3 Innovus database by using 
the Retrospective Analysis for Diabetes Action and Reporting (RADAR) tool. 
METHODS: i3 Innovus data assets including medical and pharmacy claims from May 
2006 to May 2008 were used in the RADAR tool to assess the yearly rate of glyco-
sylated hemoglobin (HbA1c) testing and low-density lipoprotein-cholesterol (LDL-C) 
screening. Other HEDIS comprehensive diabetes care–related measures reported by 
the RADAR tool included the rate of patients with (a) hypertension; (b) nephropathy; 
and (c) retinopathy. Variables such as demographic, clinical, pharmacy, and medical 
utilization patterns along with medication adherence were also reported. RESULTS: 
A total of 287,195 patients with diabetes were identiﬁed, with 92% of the patients 
identiﬁed as having type 2 diabetes. Mean age of the patients was 53 years, and 52% 
were male. Over 70% of the patients with diabetes had cardiovascular risk factors 
such as hypertension; 4%, 13%, and 11% of the diabetes population had nephropa-
thy, neuropathy, and retinopathy, respectively. Sixty-seven percent of the diabetes 
patients received HbA1c testing, while 71% of the patients received LDL-C screening 
within one year. Testing within one year was less than the national HEDIS Medicaid 
25th percentile level (74.4%) for HbA1c and greater for LDL-C screening (66.9%). 
The RADAR tool effectively evaluated the selected HEDIS comprehensive diabetes 
care measures in the i3 Innovus database. CONCLUSIONS: In this population, LDL-C 
screenings within one year for diabetes patients were above the national HEDIS low-
performance level, while HbA1c testing within one year for diabetes patients was 
below the low-performance level, utilizing the RADAR tool for analyses. These ﬁnd-
ings indicate an opportunity for improvement.
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OBJECTIVES: Type 2 diabetes mellitus is serious condition associated of chronic 
complications whose economic impact on both patients and society is constantly 
increasing. Diabetics are the 4st in the drug spending in Slovakia. Our objectives was 
to explore drug costs for diabetes and besides the costs to explore also drug consump-
tion and number treated patients with antidiabetics. METHODS: The data on drugs 
consumption were from national databases IMS Health and Pharmadata Ltd. with 
293.935 diabetic patients cohort data in 4 years. To look into the impact of the drug 
policies in the Slovak Republic in 2006–2009. We calculated the impact of several 
regulatory measures on the size of the market and health insurance expenditure. 
Among the evaluated measures were: a) Lowering the VAT for drugs from 19% to 
10%, effective from 2007 b) ﬂat price cut in 2007 (-6.6%) and in 2008 (-7.4%) c) 
introduction of degressive mark-up for wholesalers and for pharmacies d) ﬁrst and 
second rounds of the international reference pricing for all drugs in 2009. RESULTS: 
The total antidiabetics volume (oral antidiabetics + insulin) of the Slovak market in 
2009 was °38.9 mil in manufacturers´ prices. 5% of the population with type 2 dia-
betes accounted for 8% of the total health care expenditure in Slovakia. In 2006 to 
2009 number of treated patients with antidiabetics increased by 11%. In 2006 to 2009 
7 new antidiabetics (molecules) entered the market. The regression results (40.0 vs 
°38.9 mil) suggested a positive relationship between the reimbursement price and 
